Home › Funds › Cormorant Asset Management, LP › DRUG
Cormorant Asset Management, LP position in DRUG
BRIGHT MINDS BIOSCIENCES INC · Health Care
Cormorant Asset Management, LP reported holding 900,000 shares of DRUG (BRIGHT MINDS BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$63.2M, representing 3.24% of its reported portfolio and ranking #11 among its reported holdings. Cormorant Asset Management, LP has disclosed DRUG holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's DRUG position evolved
Cormorant Asset Management, LP first disclosed a stake in DRUG in Q4 2024 at 1,059,331 shares (US$38.2M). The position peaked in Q4 2025 at 1,059,331 shares, worth US$82.7M. Across 7 filings, Cormorant Asset Management, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 900,000 shares valued at US$63.2M — a reduction of -159,331 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 1.06M | $38.16M | New |
| Q1 2025 | 1.06M | $38.21M | Hold |
| Q2 2025 | 1.06M | $27.66M | Hold |
| Q3 2025 | 1.06M | $64.26M | Hold |
| Q4 2025 | 1.06M | $82.67M | Hold |
| Q1 2026 | 1.06M | $77.30M | Hold |
| Q2 2026 | 900.00K | $63.18M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DRUG and 13F data
DRUG (BRIGHT MINDS BIOSCIENCES INC) is a Health Care company. 77 other funds we track also report a position in DRUG — the largest reported positions include Vivo Capital, LLC (US$39.1M), Vestal Point Capital, LP (US$38.3M), BRAIDWELL LP (US$34.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DRUG
- Vivo Capital, LLC 557.17K sh · $39.11M · Q2 2026
- Vestal Point Capital, LP 545.00K sh · $38.26M · Q2 2026
- BRAIDWELL LP 483.82K sh · $33.96M · Q2 2026
- Parkman Healthcare Partners LLC 205.05K sh · $14.39M · Q2 2026
- MPM BioImpact LLC 202.11K sh · $14.19M · Q2 2026
- GREAT POINT PARTNERS LLC 109.60K sh · $7.69M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 92.75K sh · $6.51M · Q2 2026
- Ikarian Capital, LLC 88.95K sh · $6.24M · Q2 2026
- Sio Capital Management, LLC 73.95K sh · $5.19M · Q2 2026
- B Group, Inc. 67.50K sh · $4.74M · Q2 2026
- Artia Global Partners LP 38.41K sh · $2.70M · Q2 2026
- KVP Capital Advisors, LP 31.81K sh · $2.23M · Q2 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held DRUG?
Cormorant Asset Management, LP has disclosed DRUG holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Cormorant Asset Management, LP's current position in DRUG?
As of Q2 2026, Cormorant Asset Management, LP holds 900.00K shares of DRUG (BRIGHT MINDS BIOSCIENCES INC), valued at $63.18M, representing 3.24% of its reported portfolio and ranking #11.
Has Cormorant Asset Management, LP been buying or selling DRUG?
In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in DRUG. The position peaked in Q4 2025 at 1.06M shares.
Which other funds hold DRUG?
Other major institutional holders of DRUG include Vivo Capital, LLC, Vestal Point Capital, LP, BRAIDWELL LP, among 77 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.